en عفوني Infectious disease پژوهشي Research <div style="text-align: justify;"><span style="font-size:11pt"><span style="line-height:normal"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><i><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Background & Objective:</span></span></span></i></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"> Many different combination regimens have been used for the treatment of patients infected with human immunodeficiency viruses (HIV). This study aimed to compare the efficacy of two antiviral drugs for the treatment of HIV-infected patients. </span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><i><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Materials & Methods:</span></span></span></i></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"> This cross-sectional study was performed on HIV-positive patients in Fasa, Southwest Iran. Eighty patients were enrolled in the investigation who were then randomly divided into two groups and treated plus vonavir (tenofovir-emtricitabine-efavirenz) and cobavir (lamivudine-zidovudine) with efavirenz for six months. Blood samples collected from all patients were examined for viral load every six months using Real-time PCR and CD₄changes by flow cytometry. </span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><i><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Result:</span></span></span></i></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"> During the six months of treatment, the CD₄ response was not significantly increased in group one, treated with vonavir. In contrast, the CD₄ value showed a significant increasing trend during the treatment course in group two treated with cobavir-efavirenz (P=0.003). However, overall, there was no statistically significant difference between the CD₄ responses of the two groups (P=0.361). In addition, the plasma viral load was significantly suppressed in both regimens (P< 0.05). </span></span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span style="unicode-bidi:embed"><span sans-serif="" style="font-family:Calibri,"><b><i><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Conclusion</span></span></span></i></b><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">:</span></span></span></b> <span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Hence, the two regimens (cobavir-efavirenz, and vobavir) showed the same efficacy on HIV patients according to the same suppression of viral load, and CD₄ response in this region. However, inclusion of more samples is needed and more studies are suggested in order to confirm our results as well.</span></span></span></span></span></span></span><br> &nbsp;</div> Tenofovir-Emtricitabine-Efavirenz, Lamivudine-Zidovudine, HIV, CD4, Viral load, Iran 319 324 http://jabs.fums.ac.ir/browse.php?a_code=A-10-1670-1&slc_lang=en&sid=1 Saeideh Honarmand سعیده هنرمند saideh1994.7@gmail.com 100319475328460026557 100319475328460026557 No Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی فسا، فسا، ایران Zahra Montaseri زهرا منتصری montaserizahra90@gmail.com 100319475328460026558 100319475328460026558 Yes Department of Infectious Diseases, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran گروه بیماری‌های عفونی، دانشکده پزشکی، دانشگاه علوم پزشکی فسا، فسا، ایران Mehdi Sharafi مهدی شرفی Mehdisharafi_2002@yahoo.com 100319475328460026559 100319475328460026559 No Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی شیراز، شیراز، ایران Sohrab Najafipoor سهراب نجفی پور sohrabnajafipour@yahoo.com 100319475328460026560 100319475328460026560 No Department of Microbiology, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran گروه میکروبیولوژی، دانشکده پزشکی، دانشگاه علوم پزشکی فسا، فسا، ایران